IN.PACT Admiral Paclitaxelcoated PTA Balloon Catheter; IN.PACT 018 Paclitaxel-coated PTA Balloon Catheter
Medtronic, Inc. · Decision date Sep 16, 2025
What did the FDA decide?
FDA records P140010/S100 as a supplement to PMA P140010, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 16, 2025.
FDA approval order statement
an update to the laser-etching software for etching luer components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140010/S100
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- ONU
- Decision code
- OK30
- Decision date
- Sep 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
- Applicant
- Medtronic, Inc.
- Product code
- ONU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140010 · Original PMA
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax
P140010/S097 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S099 · Related supplement
IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S100 received
Application receipt date recorded by FDA.
P140010/S100 · FDA decision
30-Day Notice
P140010/S091 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax
P140010/S101 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S098 · Related supplement
IN.PACT 018 Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
P140010/S102 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter; IN.PACT 018 Paclitaxel-Coated
P140010/S103 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
P140010/S104 · Related supplement
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter; IN.PACT 018 Paclitaxel-Coated
P140010/S105 · Related supplement
IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PT A) Balloon Catheter
P140010/S106 · Related supplement
IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Timeline entries are records held by MedtechLedger for P140010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Dec 30, 2014 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Jan 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 13, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Mar 6, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Apr 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 1, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 21, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code ONU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Ranger Paclitaxel-Coated Balloon CatheterP190019/S043 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 4, 2026 | FDA |
Lutonix 035 Drug Coated Balloon CatheterP130024/S045 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
Ranger Paclitaxel-Coated PTA Balloon CatheterP190019/S040 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | May 1, 2026 | FDA |
RANGER Paclitaxel-Coated PTA Balloon CatheterP190019/S042 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Apr 24, 2026 | FDA |
| The Spectranetics Corp. | PMA supplement | Mar 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P140010/S100
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
